Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry. The Health & Nutrition segment produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries. It has a strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. The company was founded in 1843 and is headquartered in Hørsholm, Denmark.

Chr. Hansen Holding A/S

Chr. Hansen A/S is involved in biosolutions, focusing on the improvement of food, plant, animal, and human health through biological products. It offers food cultures and enzymes, microbial solutions for plant health, and probiotics for human health, self-described as a leading biosolutions partner.

Chr. Hansen A/S

Biotechnology Research

Novonesis

Novonesis Animal Health & Nutrition

Novonesis Human Health

Novonesis Dairy

Novonesis Pet Health & Nutrition

The Probiotics Institute by Chr. Hansen

Chr. Hansen | 126,787 followers on LinkedIn. Chr. Hansen has combined with Novozymes to become Novonesis: linkedin.com/company/novonesis. This global biosolutions company of 10,000 people is transforming how the world produces, consumes and lives.

Enterprise Architect at Radiometer Medical

Sten Mohr

Director, Head of Group Tax at Chr. Hansen Holding A/S

Morten von Jessen

David Carpenter

Jakob Nielsen

Chr. Hansen

Welcome to the era of biosolutions. Welcome to Novonesis . The proposed combination of Chr. Hansen and Novozymes is now successfully completed. Novonesis is a world-leading biosolutions partner for better business, healthier lives and a healthier planet. The combined company brings together 10,000 employees worldwide and expertise that spans more than 30 different industries. Our CEO Ester Baiget says: “Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live. And we have gathered the brightest minds and together with my 10,000 colleagues, we will unlock the limitless potential of biosolutions.” Cees de Jong , our Chair of the Board of Directors, adds his perspective: “I am pleased to witness the realization of the Novozymes and Chr. Hansen combination, creating a true global biosolutions leader. We will continue to create powerful biosolutions for our customers and partners based on our more than 100 years of innovation and application expertise. Together, we will serve as a growth partner to our customers; a value creator to our shareholders; and a company that has a significant, positive impact on society and the planet. Novonesis builds on a shared heritage of sustainability leadership and will keep leading the way.” Learn more in the press release here: https://lnkd.in/dNKhHu66 Follow Novonesis to keep updated on our future journey as a new company. #novonesis #newbeginning #biosolutions

It's time for the era of #biosolutions . Learn about biology's tiny but mighty agents of change that are at the heart of Novonesis . Find more about the era of biosolutions here: https://lnkd.in/d_cZZAk9 #novonesis #newbeginning #biosolutions

Happy New Year! 2024 has arrived, a monumental year for Chr. Hansen marking our 150th anniversary as well as a new beginning as part of Novonesis (pending final authority approval). In 1874, the company was founded on a groundbreaking discovery that revolutionized the industrial dairy production in the making. Interestingly, the same product – purified, standardized animal rennet – is still in our portfolio today. Roughly speaking, the next turning point took place a hundred years later with the invention of DVS® – direct vat set – cultures. This allowed dairies to pour concentrated starter cultures directly into the milk, saving time and costs and ensuring excellent, uniform quality of their finished product. The new millennium saw profound changes involving new ownership, new business areas, a new corporate strategy strongly committed to sustainability and, ultimately, the announcement in late 2022 of the proposed combination with Novozymes to form a leading, global biosolutions partner. As we approach Day 1 of this combination, let’s pay tribute to the legacy we are bringing into the future. If you’re curious, have a look at our historic timeline ( https://lnkd.in/d9Fj8VwG ) featuring special highlights throughout our 150 years of existence. Cheers to former colleagues and business partners who were part of making Chr. Hansen what it is today – and what it will become!

Season's greetings! As we are about to wrap up 2023, we want to take the opportunity to thank all our followers for a great year – and a very special year, probably the last as Chr. Hansen. It is always exciting what a new year will bring, and 2024 is no exception. Not only does it mark the 150th anniversary of Chr. Hansen’s foundation; it also marks a new beginning, as we expect to combine with Novozymes in the first quarter of 2024 following regulatory approval and together transform into Novenesis – a global biosolutions partner 🌿🌍 We wish you and your loved ones happy holidays, season’s greetings and a happy and prosperous new year!

And the winners of the Above and Beyond award are …! Today, we are celebrating five awesome colleagues, who have gone the extra mile to live our unique culture through the exciting year of 2023. Great nominations have been flying in from across the organization and finally, we can reveal the winners 👇

Coming soon: A new beginning. A new name: Novonesis ✨ We are happy to announce that Novonesis will be the new company name for the future combination of Novozymes and Chr. Hansen*. The name means 'A new beginning' derived from the Greek word 'genesis', which means 'beginning'. Together, we will start an era of biosolutions to help solve some of the biggest challenges facing humanity – using biology. *The name Novonesis will be used once the proposed combination is completed. We expect that to take place in the first quarter of 2024 following regulatory approval. Until final merger control approvals are received, and the proposed combination completes, Novozymes and Chr. Hansen operate as completely separate companies. Learn more about the name in the video below or in this press release: https://lnkd.in/gvMJv-un

Say cheese to innovation! 🧀 Exciting news from the world of plant-based cheese: Carmen Masiá Calabuig , a dedicated PhD student at Chr. Hansen, is leading groundbreaking research in collaboration with the University of Copenhagen's Food Science Department. Carmen is currently putting a final touch on her PhD project “Plant-based cheese evolution” which she has been working on since 2020. Carmen's PhD project showcases the power of lactic acid bacteria fermentation to craft a climate-friendly, plant-based cheese with sensory properties mirroring its dairy counterpart. It's a flavorful victory for sustainability and taste buds alike! Discover how Carmen’s passion for biology started and learn what it’s like to do an industrial PhD at Chr. Hansen.

The UN/FAO has designated today as World Soil Day to focus attention on the importance of healthy soil and advocate for its sustainable management. Healthy soil is crucial in supporting sustainable agriculture and protecting plants from harm and disease. At Chr. Hansen Plant Health we take soil health seriously. Our proven biological solutions help increase enzymatic activity in the soil to improve its health and, in turn, the health of crops – crucial in supporting sustainable agriculture. Read more at: https://lnkd.in/gKCa_ZSj www.fao.org/world-soil-day

As World Antimicrobial Awareness Week draws to a close, let's reflect on the critical issue of antibiotic resistance and how we can make a positive impact. While many factors are out of our control, here are four actionable steps we can all take to mitigate the impact of antibiotic resistance, both at the local and global levels. Let's continue the dialogue and work towards a future where antibiotics remain a powerful tool in the fight against infections. Together, we can make a difference! 💪

Earlier this week, the biosolutions sector was gathered at the first-ever Biosolutions High Level Summit in Copenhagen, featuring a great line-up of prominent speakers, including Danish Minister for Industry, Business, and Financial Affairs Morten Bødskov , the Danish Minister for Food & Agri, Jacob Jensen , Director of Tænketanken EUROPA Lykke Friis , and our colleague David Zilber, former Noma-chef and fermentation expert, who delivered a keynote speech about the power of fermentation. “The dawn of civilized cultures, cities, societies were based on fermentation of some of humanity’s first domesticated species …. And when microbes come into the picture as solutions to a human problem, they have the abilities that you couldn’t even dream of. They evolve, they problem solve, they iterate,” said David. The breadth and depth of biosolutions were showcased. Fermented foods, plant-based burgers by Matr, biobricks by Mason, biobased fabrics for clothing by Henrik Vibskov and Pond, fermented binder for asphalt Visibuilt. Solutions inspired by nature, based on biomaterials, and developed to address some of the world’s biggest challenges 🌍 The sector is gaining momentum and has moved up on the agenda! Thanks to Alliance for Biosolutions , Novo Nordisk Foundation and DI Bio for uniting such a powerhouse of start-ups, funds, investors, decision-makers, businesses, and scientists committed to shaping a future inspired by nature for nature 🌱

	Aug '14	Aug '15	Aug '16	Aug '17	Aug '18	Aug '19	Aug '20	Aug '21	Aug '22	Aug '23
net income	195.10M -	232.50M 19.17%	255.60M 9.94%	305.70M 19.60%	320.20M 4.74%	340.90M 6.46%	313M 8.18%	276.20M 11.76%	320.90M 16.18%	227M 29.26%
depreciation and amortization	51.90M -	53.90M 3.85%	56.20M 4.27%	61M 8.54%	63.80M 4.59%	64.60M 1.25%	83.90M 29.88%	101.20M 20.62%	107.10M 5.83%	113.90M 6.35%
deferred income tax					-92M -		-39.30M -
stock based compensation	3M -	3.30M 10%	2.40M 27.27%	2.50M 4.17%	1.50M 40%	400K 73.33%	-500K 225%	3.90M 880.00%	7.90M 102.56%
change in working capital	-11.80M -	-7.70M 34.75%	100K 101.30%	-30.50M 30,600%	-27.50M 9.84%	-24.10M 12.36%	17.20M 171.37%	-5.10M 129.65%	-32.50M 537.25%
accounts receivables
inventory
accounts payables
other working capital
other non cash items	-61.80M -	-60.50M 2.10%	-69.50M 14.88%	-55M 20.86%	36.40M 166.18%	-83.20M 328.57%	-9.70M 88.34%	-65.40M 574.23%	-94.60M 44.65%	-24M 74.63%
net cash provided by operating activities	176.40M -	221.50M 25.57%	244.80M 10.52%	283.70M 15.89%	302.40M 6.59%	298.60M 1.26%	364.60M 22.10%	310.80M 14.76%	308.80M 0.64%	316.90M 2.62%
investments in property plant and equipment	-62.80M -	-70.50M 12.26%	-78.10M 10.78%	-106M 35.72%	-107.90M 1.79%	-139.60M 29.38%	-118.80M 14.90%	-155.90M 31.23%	-141.60M 9.17%	-116.20M 17.94%
acquisitions net			-169.40M -	-73M 56.91%		-9.80M -	-662.70M 6,662.24%	-325.60M 50.87%
purchases of investments
sales maturities of investments
other investing activites	-11.20M -	-15.30M 36.61%	-15.30M 0%	-12.60M 17.65%	900K 107.14%	67.80M 7,433.33%	-26M 138.35%	766M 3,046.15%	-10.80M 101.41%	-60.10M 456.48%
net cash used for investing activites	-61.80M -	-70.40M 13.92%	-244.40M 247.16%	-176.50M 27.78%	-107M 39.38%	-81.60M 23.74%	-807.50M 889.58%	284.50M 135.23%	-152.40M 153.57%	-176.30M 15.68%
debt repayment	-375M -	-8.80M 97.65%	-24.90M 182.95%	-170.80M 585.94%	-35.60M 79.16%	-277.80M 680.34%	-394M 41.83%	-1.21B 207.77%	-167.10M 86.22%	-269.50M 61.28%
common stock issued	27.70M -	8M 71.12%	17.50M 118.75%	24.60M 40.57%	1.10M 95.53%			680.20M -
common stock repurchased	-80M -	-38M 52.50%		-20.10M -	-4.70M 76.62%	-5.30M 12.77%		-10.40M -	-9.20M 11.54%
dividends paid	-111.60M -	-181.40M 62.54%	-82.10M 54.74%	-192.20M 134.10%	-216.90M 12.85%	-224.30M 3.41%	-124.70M 44.40%	-115.80M 7.14%	-115.90M 0.09%	-124.70M 7.59%
other financing activites	404.90M -	88.50M 78.14%	132.80M 50.06%	416M 213.25%	60.50M 85.46%	306.90M 407.27%	975.50M 217.86%	21.40M 97.81%	150M 600.93%	235.50M 57.00%
net cash used provided by financing activities	-134M -	-131.70M 1.72%	43.30M 132.88%	-150.50M 447.58%	-195.60M 29.97%	-200.50M 2.51%	456.80M 327.83%	-637.20M 239.49%	-142.20M 77.68%	-158.70M 11.60%
effect of forex changes on cash	-500K -	-600K 20%	-300K 50%	-3.50M 1,066.67%	-3.70M 5.71%	1.80M 148.65%	-5.10M 383.33%	800K 115.69%	13.50M 1,587.50%	-8.70M 164.44%
net change in cash	-19.90M -	18.80M 194.47%	43.40M 130.85%	-46.80M 207.83%	-3.90M 91.67%	18.30M 569.23%	8.80M 51.91%	-41.10M 567.05%	27.70M 167.40%	-26.80M 196.75%
cash at beginning of period	77.50M -	57.60M 25.68%	76.40M 32.64%	119.80M 56.81%	73M 39.07%	69.10M 5.34%	87.40M 26.48%	96.20M 10.07%	55.10M 42.72%	82.80M 50.27%
cash at end of period	57.60M -	76.40M 32.64%	119.80M 56.81%	73M 39.07%	69.10M 5.34%	87.40M 26.48%	96.20M 10.07%	55.10M 42.72%	82.80M 50.27%	56M 32.37%
operating cash flow	176.40M -	221.50M 25.57%	244.80M 10.52%	283.70M 15.89%	302.40M 6.59%	298.60M 1.26%	364.60M 22.10%	310.80M 14.76%	308.80M 0.64%	316.90M 2.62%
capital expenditure	-62.80M -	-70.50M 12.26%	-78.10M 10.78%	-106M 35.72%	-107.90M 1.79%	-139.60M 29.38%	-118.80M 14.90%	-155.90M 31.23%	-141.60M 9.17%	-116.20M 17.94%
free cash flow	113.60M -	151M 32.92%	166.70M 10.40%	177.70M 6.60%	194.50M 9.45%	159M 18.25%	245.80M 54.59%	154.90M 36.98%	167.20M 7.94%	200.70M 20.04%

CHR

COM:CHR-HANSEN

Chr. Hansen A/S

Last Close

553.00

30/01 15:59

Market Cap

72.33B

Beta: -

Volume Today

407.54K

Avg: -

Preview